<p>RNS 编号：7665Q 阿伯丁集团有限公司 2026 年 1 月 28 日</p>
<p>表格 8.3</p>
<p>公开开盘位置披露/交易披露</p>
<p>由持有相关证券 1% 或以上权益的个人</p>
<p>收购守则第 8.3 条（“守则”）</p>
<p>1. 关键信息</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露者的全名：</td>
<td>阿伯丁集团有限公司</td>
</tr>
<tr>
<td>(b) 如果与 1(a) 不同，权益和空头头寸的所有者或控制者：</td>
<td></td>
</tr>
<tr>
<td>提名或载体公司的命名是不够的。对于信托，必须命名受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>(c) 与本表格相关的要约人/被要约人名称：</td>
<td></td>
</tr>
<tr>
<td>每个要约人/被要约人使用单独的表格</td>
<td>牛津生物医学有限公司</td>
</tr>
<tr>
<td>(d) 如果是与要约人/被要约人相关的豁免基金经理，请说明并指定要约人/被要约人的身份：</td>
<td></td>
</tr>
<tr>
<td>(e) 持有/交易的日期：</td>
<td></td>
</tr>
<tr>
<td>对于开盘位置披露，请说明披露前的最新可行日期</td>
<td>2026 年 1 月 27 日</td>
</tr>
<tr>
<td>(f) 除上述 1(c) 中的公司外，披露者是否还在披露任何其他要约方？</td>
<td></td>
</tr>
<tr>
<td>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>否</td>
</tr>
</tbody>
</table>
<p>2. 披露者的持仓情况</p>
<p>如果在 1(c) 中提到的要约人或被要约人的多个类别的相关证券中有持仓或认购权需要披露，请为每个额外类别的相关证券复制表格 2(a) 或 (b)（视情况而定）。</p>
<p>(a) 与披露相关的要约人或被要约人的相关证券的权益和空头头寸（如有）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别：</td>
<td>50 便士普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>权益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券：</td>
<td>1,882,814</td>
<td>1.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 现金结算衍生品：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 股票结算衍生品（包括期权）和购买/出售协议：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计：</td>
<td>1,882,814</td>
<td>1.56</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>所有权益和所有空头头寸应予以披露。</p>
<p>任何开放的股票结算衍生品头寸（包括交易期权）或购买或出售相关证券的协议应在补充表格 8（开放头寸）中提供详细信息。</p>
<p>(b) 认购新证券的权利（包括董事和其他员工期权）</p>
<ul>
<li>相关证券类别：</li>
<li>详细信息，包括相关权利的性质和相关百分比：</li>
</ul>
<p>3. 披露者的交易（如有）</p>
<p>如果在 1(c) 中提到的要约人或被要约人的多个类别的相关证券中有交易，请为每个额外类别的相关证券复制表格 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
<p>所有价格和其他货币金额的货币单位应予以说明。</p>
<p>(a) 购买和销售</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>50 便士普通股</td>
</tr>
<tr>
<td>购买/销售</td>
<td>购买</td>
</tr>
<tr>
<td>证券数量</td>
<td>1,744</td>
</tr>
<tr>
<td>单位价格</td>
<td>英镑 8.690</td>
</tr>
</tbody>
</table>
<p>(b) 现金结算衍生品交易</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如 CFD</li>
<li>交易性质，例如开立/平仓多头/空头头寸，增加/减少多头/空头头寸</li>
<li>参考证券数量</li>
<li>单位价格</li>
</ul>
<p>(c) 股票结算衍生品交易（包括期权）</p>
<p>(i) 写入、出售、购买或变更</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>写入、购买、出售、变更等。</li>
<li>与期权相关的证券数量</li>
<li>单位行使价格</li>
<li>类型，例如美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付/收到的期权费用</li>
</ul>
<p>(ii) 行使</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>行使/对抗行使</li>
<li>证券数量</li>
<li>单位行使价格</li>
</ul>
<p>(d) 其他交易（包括认购新证券）</p>
<ul>
<li>相关证券类别</li>
<li>交易性质，例如认购、转换</li>
<li>详细信息</li>
<li>单位价格（如适用）</li>
</ul>
<p>4. 其他信息</p>
<p>(a) 赔偿和其他交易安排</p>
<ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使披露者与要约方或与要约方一致行动的任何人进行交易或避免交易：不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
<p>(b) 与期权或衍生品相关的协议、安排或理解</p>
<ul>
<li>披露者与任何其他人之间的任何协议、安排或理解的详细信息，无论是正式还是非正式，涉及：(i) 任何相关证券在任何期权下的投票权；或 (ii) 任何衍生品所参考的任何相关证券的投票权或未来的收购或处置：如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
<p>(c) 附件</p>
<ul>
<li>是否附有补充表格 8（开放头寸）？</li>
<li>否</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>2026 年 1 月 28 日</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Frederic Osei</td>
</tr>
<tr>
<td>电话号码 *：</td>
<td>+44 131 372 9132</td>
</tr>
</tbody>
</table>
<p>根据守则第 8 条的公开披露必须向监管信息服务进行。</p>
<p>面板的市场监测单位可就守则的披露要求进行咨询，电话：+44 (0) 20 7638 0129。</p>
<p>* 如果披露者是自然人，则无需提供电话号码，只需向面板的市场监测单位提供联系信息。</p>
<p>守则可在面板网站 www.thetakeoverpanel.org.uk 上查看。</p>
<p>此信息由伦敦证券交易所的新闻服务 RNS 提供。RNS 已获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
<p>RNS 可能会使用您的 IP 地址来确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并将此类分析以匿名方式与他人分享，作为我们商业服务的一部分。如需了解 RNS 和伦敦证券交易所如何使用您提供的个人数据，请参阅我们的隐私政策。END RETEAAFPAEKKEFA</p>

ABDN

<p>阿伯丁集团 PLC 披露了其在牛津生物医学 PLC 的持股情况，报告拥有 1,882,814 股，占该公司相关证券的 1.56%。该披露是根据收购守则第 8.3 条进行的，最新持股情况截至 2026 年 1 月 27 日。报告包括近期交易的详细信息，其中包括以每股 8.690 英镑购买 1,744 股。没有报告与该证券相关的其他协议或安排。该披露由弗雷德里克·奥塞于 2026 年 1 月 28 日发布</p>

<p>RNS Number : 7665Q Aberdeen Group PLC 28 January 2026</p>
<div class="lb-trans"><p>RNS 编号：7665Q 阿伯丁集团有限公司 2026 年 1 月 28 日</p>
</div><p>FORM 8.3</p>
<div class="lb-trans"><p>表格 8.3</p>
</div><p>PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY</p>
<div class="lb-trans"><p>公开开盘位置披露/交易披露</p>
</div><p>A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE</p>
<div class="lb-trans"><p>由持有相关证券 1% 或以上权益的个人</p>
</div><p>Rule 8.3 of the Takeover Code (the &#34;Code&#34;)</p>
<div class="lb-trans"><p>收购守则第 8.3 条（“守则”）</p>
</div><p>1. KEY INFORMATION</p>
<div class="lb-trans"><p>1. 关键信息</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) Full name of discloser:</td>
<td>Aberdeen Group plc</td>
</tr>
<tr>
<td>(b) Owner or controller of interests and short positions disclosed, if different from 1(a):<br/>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</td>
<td></td>
</tr>
<tr>
<td>(c) Name of offeror/offeree in relation to whose relevant securities this form relates:<br/>Use a separate form for each offeror/offeree</td>
<td>Oxford Biomedica plc</td>
</tr>
<tr>
<td>(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:</td>
<td></td>
</tr>
<tr>
<td>(e) Date position held/dealing undertaken:<br/>For an opening position disclosure, state the latest practicable date prior to the disclosure</td>
<td>27 January 2026</td>
</tr>
<tr>
<td>(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?<br/>If it is a cash offer or possible cash offer, state &#34;N/A&#34;</td>
<td>No</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(a) 披露者的全名：</td>
<td>阿伯丁集团有限公司</td>
</tr>
<tr>
<td>(b) 如果与 1(a) 不同，权益和空头头寸的所有者或控制者：</td>
<td></td>
</tr>
<tr>
<td>提名或载体公司的命名是不够的。对于信托，必须命名受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>(c) 与本表格相关的要约人/被要约人名称：</td>
<td></td>
</tr>
<tr>
<td>每个要约人/被要约人使用单独的表格</td>
<td>牛津生物医学有限公司</td>
</tr>
<tr>
<td>(d) 如果是与要约人/被要约人相关的豁免基金经理，请说明并指定要约人/被要约人的身份：</td>
<td></td>
</tr>
<tr>
<td>(e) 持有/交易的日期：</td>
<td></td>
</tr>
<tr>
<td>对于开盘位置披露，请说明披露前的最新可行日期</td>
<td>2026 年 1 月 27 日</td>
</tr>
<tr>
<td>(f) 除上述 1(c) 中的公司外，披露者是否还在披露任何其他要约方？</td>
<td></td>
</tr>
<tr>
<td>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>否</td>
</tr>
</tbody>
</table>
</div><p>2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE</p>
<div class="lb-trans"><p>2. 披露者的持仓情况</p>
</div><p>If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.</p>
<div class="lb-trans"><p>如果在 1(c) 中提到的要约人或被要约人的多个类别的相关证券中有持仓或认购权需要披露，请为每个额外类别的相关证券复制表格 2(a) 或 (b)（视情况而定）。</p>
</div><p>(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)</p>
<div class="lb-trans"><p>(a) 与披露相关的要约人或被要约人的相关证券的权益和空头头寸（如有）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security:</td>
<td>50p ordinary</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interests</td>
<td>Short positions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number</td>
<td>%</td>
<td>Number</td>
<td>%</td>
</tr>
<tr>
<td>(1) Relevant securities owned and/or controlled:</td>
<td>1,882,814</td>
<td>1.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) Cash-settled derivatives:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) Stock-settled derivatives (including options) and agreements to purchase/sell:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL:</td>
<td>1,882,814</td>
<td>1.56</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别：</td>
<td>50 便士普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>权益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
</tr>
<tr>
<td>(1) 拥有和/或控制的相关证券：</td>
<td>1,882,814</td>
<td>1.56</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(2) 现金结算衍生品：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(3) 股票结算衍生品（包括期权）和购买/出售协议：</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计：</td>
<td>1,882,814</td>
<td>1.56</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>All interests and all short positions should be disclosed.</p>
<div class="lb-trans"><p>所有权益和所有空头头寸应予以披露。</p>
</div><p>Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).</p>
<div class="lb-trans"><p>任何开放的股票结算衍生品头寸（包括交易期权）或购买或出售相关证券的协议应在补充表格 8（开放头寸）中提供详细信息。</p>
</div><p>(b) Rights to subscribe for new securities (including directors' and other employee options)</p>
<div class="lb-trans"><p>(b) 认购新证券的权利（包括董事和其他员工期权）</p>
</div><ul>
<li>Class of relevant security in relation to which subscription right exists:</li>
<li>Details, including nature of the rights concerned and relevant percentages:</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别：</li>
<li>详细信息，包括相关权利的性质和相关百分比：</li>
</ul>
</div><p>3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE</p>
<div class="lb-trans"><p>3. 披露者的交易（如有）</p>
</div><p>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</p>
<div class="lb-trans"><p>如果在 1(c) 中提到的要约人或被要约人的多个类别的相关证券中有交易，请为每个额外类别的相关证券复制表格 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
</div><p>The currency of all prices and other monetary amounts should be stated.</p>
<div class="lb-trans"><p>所有价格和其他货币金额的货币单位应予以说明。</p>
</div><p>(a) Purchases and sales</p>
<div class="lb-trans"><p>(a) 购买和销售</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security</td>
<td>50p ordinary</td>
</tr>
<tr>
<td>Purchase/sale</td>
<td>Purchase</td>
</tr>
<tr>
<td>Number of securities</td>
<td>1,744</td>
</tr>
<tr>
<td>Price per unit</td>
<td>GBP 8.690</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>50 便士普通股</td>
</tr>
<tr>
<td>购买/销售</td>
<td>购买</td>
</tr>
<tr>
<td>证券数量</td>
<td>1,744</td>
</tr>
<tr>
<td>单位价格</td>
<td>英镑 8.690</td>
</tr>
</tbody>
</table>
</div><p>(b) Cash-settled derivative transactions</p>
<div class="lb-trans"><p>(b) 现金结算衍生品交易</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product descriptione.g. CFD</li>
<li>Nature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short position</li>
<li>Number of reference securities</li>
<li>Price per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如 CFD</li>
<li>交易性质，例如开立/平仓多头/空头头寸，增加/减少多头/空头头寸</li>
<li>参考证券数量</li>
<li>单位价格</li>
</ul>
</div><p>(c) Stock-settled derivative transactions (including options)</p>
<div class="lb-trans"><p>(c) 股票结算衍生品交易（包括期权）</p>
</div><p>(i) Writing, selling, purchasing or varying</p>
<div class="lb-trans"><p>(i) 写入、出售、购买或变更</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Writing, purchasing, selling, varying etc.</li>
<li>Number of securities to which option relates</li>
<li>Exercise price per unit</li>
<li>Typee.g. American, European etc.</li>
<li>Expiry date</li>
<li>Option money paid/ received per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>写入、购买、出售、变更等。</li>
<li>与期权相关的证券数量</li>
<li>单位行使价格</li>
<li>类型，例如美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付/收到的期权费用</li>
</ul>
</div><p>(ii) Exercise</p>
<div class="lb-trans"><p>(ii) 行使</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product descriptione.g. call option</li>
<li>Exercising/ exercised against</li>
<li>Number of securities</li>
<li>Exercise price per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>行使/对抗行使</li>
<li>证券数量</li>
<li>单位行使价格</li>
</ul>
</div><p>(d) Other dealings (including subscribing for new securities)</p>
<div class="lb-trans"><p>(d) 其他交易（包括认购新证券）</p>
</div><ul>
<li>Class of relevant security</li>
<li>Nature of dealinge.g. subscription, conversion</li>
<li>Details</li>
<li>Price per unit (if applicable)</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>交易性质，例如认购、转换</li>
<li>详细信息</li>
<li>单位价格（如适用）</li>
</ul>
</div><p>4. OTHER INFORMATION</p>
<div class="lb-trans"><p>4. 其他信息</p>
</div><p>(a) Indemnity and other dealing arrangements</p>
<div class="lb-trans"><p>(a) 赔偿和其他交易安排</p>
</div><ul>
<li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使披露者与要约方或与要约方一致行动的任何人进行交易或避免交易：不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
</div><p>(b) Agreements, arrangements or understandings relating to options or derivatives</p>
<div class="lb-trans"><p>(b) 与期权或衍生品相关的协议、安排或理解</p>
</div><ul>
<li>Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state &#34;none&#34;</li>
<li>None</li>
</ul>
<div class="lb-trans"><ul>
<li>披露者与任何其他人之间的任何协议、安排或理解的详细信息，无论是正式还是非正式，涉及：(i) 任何相关证券在任何期权下的投票权；或 (ii) 任何衍生品所参考的任何相关证券的投票权或未来的收购或处置：如果没有此类协议、安排或理解，请说明 “无”</li>
<li>无</li>
</ul>
</div><p>(c) Attachments</p>
<div class="lb-trans"><p>(c) 附件</p>
</div><ul>
<li>Is a Supplemental Form 8 (Open Positions) attached?</li>
<li>No</li>
</ul>
<div class="lb-trans"><ul>
<li>是否附有补充表格 8（开放头寸）？</li>
<li>否</li>
</ul>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure:</td>
<td>28 January 2026</td>
</tr>
<tr>
<td>Contact name:</td>
<td>Frederic Osei</td>
</tr>
<tr>
<td>Telephone number*:</td>
<td>+44 131 372 9132</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期：</td>
<td>2026 年 1 月 28 日</td>
</tr>
<tr>
<td>联系人姓名：</td>
<td>Frederic Osei</td>
</tr>
<tr>
<td>电话号码 *：</td>
<td>+44 131 372 9132</td>
</tr>
</tbody>
</table>
</div><p>Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.</p>
<div class="lb-trans"><p>根据守则第 8 条的公开披露必须向监管信息服务进行。</p>
</div><p>The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0) 20 7638 0129.</p>
<div class="lb-trans"><p>面板的市场监测单位可就守则的披露要求进行咨询，电话：+44 (0) 20 7638 0129。</p>
</div><p>*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.</p>
<div class="lb-trans"><p>* 如果披露者是自然人，则无需提供电话号码，只需向面板的市场监测单位提供联系信息。</p>
</div><p>The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.</p>
<div class="lb-trans"><p>守则可在面板网站 www.thetakeoverpanel.org.uk 上查看。</p>
</div><p>This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.</p>
<div class="lb-trans"><p>此信息由伦敦证券交易所的新闻服务 RNS 提供。RNS 已获得金融行为监管局的批准，作为英国的主要信息提供者。有关使用和分发此信息的条款和条件可能适用。如需更多信息，请联系 rns@lseg.com 或访问 www.rns.com。</p>
</div><p>RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END RETEAAFPAEKKEFA</p>
<div class="lb-trans"><p>RNS 可能会使用您的 IP 地址来确认遵守条款和条件，分析您与本通信中包含的信息的互动方式，并将此类分析以匿名方式与他人分享，作为我们商业服务的一部分。如需了解 RNS 和伦敦证券交易所如何使用您提供的个人数据，请参阅我们的隐私政策。END RETEAAFPAEKKEFA</p>
</div>

REG - 阿伯丁集团 PLC 与牛津生物医学 PLC - 表格 8.3 - 牛津生物医学 PLC